Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lundbeck/Otsuka Global Alliance Will Support Lundbeck's Move Into U.S. Psychiatry Market

This article was originally published in PharmAsia News

You may also be interested in...



Lundbeck Cuts 150 R&D Jobs To Control Costs Ahead Of Key Patent Expiry

Danish pharma increases investment in new product launches as it prepares for loss of patent protection on its lead product, escitalopram.

Lundbeck Leans On Licensing To Overcome Lexapro/Cipralex Expiry

As lead drug Lexapro/Cipralex faces genericization, Lundbeck is counting on revenues from ongoing licensing deals to fill the $1 billion hole.

New Analyses Allow Restart Of Ipsen's Palovarotene Clinical Program

Ipsen is to restart a global Phase III study of palovarotene in an ultra-rare bone disorder after additional analyses of interim data, but a partial clinical hold of the compound's use in patients aged under 14 years of age remains in place.

Related Companies

UsernamePublicRestriction

Register

SC076691

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel